Technical Coverage on Biotech Stocks — Cytori Therapeutics, Oncolytics Biotech, BioMarin Pharma, Aeterna Zentaris …
LONDON, March 19, 2015 /PRNewswire/ —Editor Note: For more information about this release, please scroll to bottom.Investor-Edge has initiated coverage on the following equities: Cytori Therapeutics Inc. (NASDAQ: CYTX), Oncolytics Biotech Inc. (NASDAQ: ONCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Aeterna Zentaris Inc. (NASDAQ: AEZS), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Cytori Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Cytori%20Therapeutics&d=19-Mar-2015&s=CYTX. On Wednesday, March 18, 2015, the NASDAQ Composite ended at 4,982.83, up 0.92%, the Dow Jones Industrial Average advanced 1.27%, to finish the day at 18,076.19, and the S&P 500 closed at 2,099.50, up 1.22%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 855.17, up 1.29%, with the index also advancing 5.11% in the previous three months. Register for your complimentary reports at the links given below. ;
Cytori Therapeutics Inc.’s stock plummeted 8.33%, to close the day at $1.21. The stock recorded a trading volume of 4.02 million shares, below its three months average volume of 4.21 million shares. The stock oscillated between $1.18 and $1.32 during the session. Over the last one month and over the past three months, Cytori Therapeutics Inc.’s shares have rallied 105.08% and 136.33%, respectively. However, the stock has lost 59.12% in the previous year. The company is trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $1.10 is above its 50-day moving average of $0.70. Additionally, Cytori Therapeutics Inc. has a Relative Strength Index (RSI) of 69.13. Sign up and read the free notes on CYTX at:
On Wednesday, shares in Oncolytics Biotech Inc. recorded a trading volume of 1.89 million shares, lower than its three months average volume of 2.02 million shares. The stock ended the day at $0.78, which was 8.92% above its previous day’s closing of $0.72, and registered an intraday range of $0.70 and $0.84. Oncolytics Biotech Inc.’s shares have advanced 4.02% in the last one month and 52.94% in the previous three months. However, the stock has declined 55.43% in the past one year. The company is trading above its 50-day moving average of $0.61. Furthermore, shares of Oncolytics Biotech Inc. have an RSI of 48.13. The complimentary notes on ONCY can be downloaded as in PDF format at:
BioMarin Pharmaceutical Inc.’s stock edged 0.91% lower, to close Wednesday’s session at $126.11, after oscillating between $123.85 and $127.54. The stock recorded a trading volume of 1.77 million shares, above its three months average volume of 1.34 million shares. Over the last one month and the previous three months, BioMarin Pharmaceutical Inc.’s shares have surged 22.01% and 37.33%, respectively. Additionally, the stock has gained 55.33% in the last one year. The company is trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $102.64 is above its 200-day moving average of $80.29. Further, BioMarin Pharmaceutical Inc.’s stock has an RSI of 85.89. Register for free on Investor-Edge and access the latest research on BMRN at:
Aeterna Zentaris Inc.’s stock finished Wednesday’s session 3.91% higher at $0.55. A total of 3.05 million shares were traded, which was above its three months average volume of 1.31 million shares. The stock moved between $0.53 and $0.58 during the session. Aeterna Zentaris Inc.’s shares have lost 18.36% in the last one month and 57.27% in the previous year. However, the stock has gained 7.25% in the past three trading sessions. The company’s shares are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $0.94 is greater than its 50-day moving average of $0.58. Aeterna Zentaris Inc.’s stock has an RSI of 43.93. The complete research on AEZS is available for free at:
On Wednesday, shares in Immunomedics Inc. fluctuated between $3.97 and $4.15 before ending the session 2.17% lower at $4.05. The stock reported a trading volume of 1.12 million shares, above its three months average volume of 0.98 million shares. Although, Immunomedics Inc.’s shares have advanced 1.00% in the last one month, it has declined 4.93% in the previous three trading sessions and 15.63% in the past one year. The company is trading above its 200-day moving average of $3.85. Moreover, shares of Immunomedics Inc. have an RSI of 47.67. Free in depth research on IMMU is available at:
About Investor-Edge.com ;
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That’s where Investor-Edge comes in. We provide a single unified platform for investors’ to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors’ package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Follow this link: